NCT06720376 Observational Prospective Turkish Inception Cohort of Uveitis and Spondyloarthritis
| NCT ID | NCT06720376 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marmara University |
| Condition | Spondylarthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-01-15 |
| Primary Completion | 2028-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-01-15 with a primary completion date of 2028-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Spondyloarthritis (SpA) encompasses a group of inflammatory rheumatic diseases characterized by axial and/or peripheral arthritis, along with extra-articular manifestations such as enthesitis, dactylitis, uveitis, and skin lesions. Axial spondyloarthritis (axSpA), the hallmark of which is chronic sacroiliitis, can progress to vertebral fusion ("bamboo spine") in advanced cases. The prevalence of axSpA varies globally, ranging from 0.1% to 1.4%, with a higher incidence in men and a typical onset in the second or third decades of life. Diagnostic approaches include imaging techniques such as sacroiliac MRI and radiographs, alongside clinical criteria like inflammatory back pain, NSAID responsiveness, peripheral arthritis, and HLA-B27 positivity. Disease management primarily involves NSAIDs, with biologics used for refractory cases, and disease activity is monitored using indices such as BASDAI and ASDAS. Acute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA, particularly associated with HLA-B27 positivity. It often presents unilaterally with redness, pain, and photophobia but can lead to severe complications if inadequately treated. Around 50% of patients with HLA-B27-positive AAU have underlying SpA, and the prevalence of uveitis increases with longer disease duration. While the link between SpA and AAU is well-established, further research is needed to determine optimal systemic treatment and follow-up protocols. This study aims to assess the prevalence and clinical characteristics of SpA in patients presenting with AAU at ophthalmology clinics.
Eligibility Criteria
Inclusion Criteria: * patients with uveitis Exclusion Criteria: * patients diagnosed spondyloarthiritis before from the uveitis attack * patients with infectious uveitis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06720376 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Spondylarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06720376 currently recruiting?
Yes, NCT06720376 is actively recruiting participants. Contact the research team at pamiratagunduz@marmara.edu.tr for enrollment information.
Where is the NCT06720376 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06720376 clinical trial?
NCT06720376 is sponsored by Marmara University. The trial plans to enroll 100 participants.